A Better Future for Bladder Cancer
A new biomarker allows effective, noninvasive screening of patients at risk of the disease
John Cucci | | Quick Read
sponsored by Acupath Labs
Bladder cancer presents a diagnostic challenge for even the best pathologists and laboratory medicine professionals. With symptoms similar to those of other urinary tract conditions and no reliable screening tests to spot malignancy, patients may experience delays in diagnosis. And these delays can affect survival – almost 90 percent of those diagnosed at stage I survive five years or more, whereas only about 10 percent of those diagnosed at stage IV achieve the same survival. To provide patients with the best possible chances, diagnostic professionals need sensitive, specific tests for bladder cancer – a problem to which URO17™ offers an effective and noninvasive solution.
Read the full article now
Log in or register to read this article in full and gain access to The Pathologist’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Pathologist magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.